284 related articles for article (PubMed ID: 21940589)
1. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
[TBL] [Abstract][Full Text] [Related]
2. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
Dósa E; Guillaume DJ; Haluska M; Lacy CA; Hamilton BE; Njus JM; Rooney WD; Kraemer DF; Muldoon LL; Neuwelt EA
Neuro Oncol; 2011 Feb; 13(2):251-60. PubMed ID: 21163809
[TBL] [Abstract][Full Text] [Related]
4. Quantitative comparison of delayed ferumoxytol T
Horváth A; Varallyay CG; Schwartz D; Toth GB; Netto JP; Barajas R; Várallyay P; Szidonya L; Firkins J; Youngers E; Fu R; Ambady P; Bogner P; Neuwelt EA
Magn Reson Med; 2018 Jul; 80(1):224-230. PubMed ID: 29205477
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
6. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
[TBL] [Abstract][Full Text] [Related]
8. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
[TBL] [Abstract][Full Text] [Related]
9. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
[TBL] [Abstract][Full Text] [Related]
10. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
Thompson EM; Guillaume DJ; Dósa E; Li X; Nazemi KJ; Gahramanov S; Hamilton BE; Neuwelt EA
J Neurooncol; 2012 Aug; 109(1):105-14. PubMed ID: 22528798
[TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size.
Hamilton BE; Barajas R; Nesbit GM; Fu R; Ambady P; Taylor M; Neuwelt EA
AJR Am J Roentgenol; 2020 Dec; 215(6):1436-1442. PubMed ID: 33052739
[No Abstract] [Full Text] [Related]
12. Comparison of Three Ultrasmall, Superparamagnetic Iron Oxide Nanoparticles for MRI at 3.0 T.
Colbert CM; Ming Z; Pogosyan A; Finn JP; Nguyen KL
J Magn Reson Imaging; 2023 Jun; 57(6):1819-1829. PubMed ID: 36250695
[TBL] [Abstract][Full Text] [Related]
13. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
14. Incidental ferumoxytol artifacts in clinical brain MR imaging.
Bowser BA; Campeau NG; Carr CM; Diehn FE; McDonald JS; Miller GM; Kaufmann TJ
Neuroradiology; 2016 Nov; 58(11):1087-1091. PubMed ID: 27704163
[TBL] [Abstract][Full Text] [Related]
15. Emerging applications for ferumoxytol as a contrast agent in MRI.
Bashir MR; Bhatti L; Marin D; Nelson RC
J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis.
Dousset V; Ballarino L; Delalande C; Coussemacq M; Canioni P; Petry KG; Caillé JM
AJNR Am J Neuroradiol; 1999 Feb; 20(2):223-7. PubMed ID: 10094342
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors.
Varallyay P; Nesbit G; Muldoon LL; Nixon RR; Delashaw J; Cohen JI; Petrillo A; Rink D; Neuwelt EA
AJNR Am J Neuroradiol; 2002 Apr; 23(4):510-9. PubMed ID: 11950637
[TBL] [Abstract][Full Text] [Related]
18. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
[TBL] [Abstract][Full Text] [Related]
19. Delineation of gliomas with various doses of MR contrast material.
Yuh WT; Nguyen HD; Tali ET; Mayr NA; Fisher DJ; Atlas SW; Carvlin MC; Drayer BP; Pollei SR; Runge VM
AJNR Am J Neuroradiol; 1994 May; 15(5):983-9. PubMed ID: 8059672
[TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
